Biosimilars Rise Is Cold Comfort For Biogen As Tecfidera Competition Bites
Signals ‘Financial Reset’ In 2021 Due To Dimethyl Fumarate Generics
Biosimilars sales rising by 8% to almost $800m in 2020 failed to offset the impact on Biogen of generic competition to its Tecfidera brand in the US.
